An antiviral small-interfering RNA simultaneously effective against the most prevalent enteroviruses causing acute hemorrhagic conjunctivitis

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 1, 2011, Pages 58-63

  Jun, Eun Jung ^a   Won, Min Ah ^a   Ahn, Jeonghyun ^a   Ko, Ara ^a   Moon, Haein ^a   Tchah, Hungwon ^a,b   Kim, Yoo Kyum ^a   Lee, Heuiran ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA; VIRUS PROTEIN; ANTIVIRUS AGENT;

ACUTE HEMORRHAGIC CONJUNCTIVITIS; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; COXSACKIE VIRUS A; COXSACKIE VIRUS A24; DRUG DESIGN; DRUG EFFICACY; DRUG SCREENING; ENTEROVIRUS; ENTEROVIRUS 70; GENE TARGETING; GENETIC SCREENING; HELA CELL; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SEQUENCE HOMOLOGY; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS GENOME; VIRUS INHIBITION; VIRUS POLYMERASE 3D GENE; CONJUNCTIVA; COXSACKIE VIRUS INFECTION; CYTOLOGY; ENTEROVIRUS INFECTION; FIBROBLAST; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; PHYSIOLOGY; RNA INTERFERENCE; VIROLOGY; VIRUS REPLICATION; WESTERN BLOTTING;

ANTIVIRAL AGENTS; BLOTTING, WESTERN; CONJUNCTIVA; CONJUNCTIVITIS, ACUTE HEMORRHAGIC; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS C, HUMAN; ENTEROVIRUS D, HUMAN; ENTEROVIRUS INFECTIONS; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENOME, VIRAL; HELA CELLS; HUMANS; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRAL STRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 79951632004     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-5051     Document Type: Article

References (43)

1. Metselaar D, Awan AM, Ensering HL. Acute haemorrhagic conjunctivitis and enterovirus 70 in Kenya. Trop Geogr Med. 1976;28:131- 136.
2. Kurokawa M, Rai SK, Ono K, Gurung R, Ruit S. Viral investigation of acute hemorrhagic conjunctivitis outbreak (2003) in Nepal using molecular methods. Southeast Asian J Trop Med Public Health. 2006;37:904-910.
3. Leonard JN, Schaffer DV. Antiviral RNAi therapy: emerging approaches for hitting a moving target. Gene Ther. 2006;13:532-540.
4. Wright PW, Strauss GH, Langford MP. Acute hemorrhagic conjunctivitis. Am Fam Physician. 1992;45:173-178.
5. Park K, Lee K, Lee J, et al. Acute hemorrhagic conjunctivitis epidemic caused by coxsackievirus A24 variants in Korea during 2002-2003. J Med Virol. 2006;78:91-97.
6. Wu D, Ke CW, Mo YL, et al. Multiple outbreaks of acute hemor-rhagic conjunctivitis due to a variant of coxsackievirus A24: Guangdong, China 2007. J Med Virol. 2008;80:1762-1768.
7. Khan A, Sharif S, Shaukat S, Khan S, Zaidi S. An outbreak of acute hemorrhagic conjunctivitis (AHC) caused by coxsackievirus A24 variant in Pakistan. Virus Res. 2008;137:150-152.
8. Moura FE, Ribeiro DC, Gurgel N, et al. Acute haemorrhagic conjunctivitis outbreak in the city of Fortaleza, northeast Brazil. Br J Ophthalmol. 2006;90:1091-1093.
9. Tavares FN, Costa EV, Oliveira SS, Nicolai CC, Baran M, da Silva EE. Acute hemorrhagic conjunctivitis and coxsackievirus A24v. Emerg Infect Dis. 2006;12:495-497.
10. Yeo DS, Seah SG, Chew JS, et al. Molecular identification of coxsackievirus A24 variant, isolated from an outbreak of acute hemorrhagic conjunctivitis in Singapore in 2005. Arch Virol. 2007; 152:2005-2016.
11. Palacios G, Oberste MS. Enteroviruses as agents of emerging infectious diseases. J Neurovirol. 2005;11:424-433.
12. Tamaki Y. Serological characterization of Cis AB antigens in Japanese family. Jinrui Idengaku Zasshi. 1975;19:335-342.
13. Fauquet CM, Mayo MA. Picornaviridae. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA, eds. Virus Taxonomy. London: Elsevier Academic Press; 2005:757-782.
14. Racaniello VR. Picornaviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Field Virology. Philadelphia: Lippin-cott Williams & Wilkins; 2007:795-838.
15. Ahn J, Joo CH, Seo I, et al. Characteristics of apoptotic cell death induced by coxsackievirus B in permissive Vero cells. Intervirol-ogy. 2003;46:245-251.
16. Feuer R, Mena I, Pagarigan RR, Harkins S, Hassett DE, Whitton JL. Coxsackievirus B3 and the neonatal CNS: the roles of stem cells, developing neurons, and apoptosis in infection, viral dissemination, and disease. Am J Pathol. 2003;163:1379-1393.
17. Ahn J, Joo CH, Seo I, Kim D, Kim YK, Lee H. All CVB serotypes and clinical isolates induce irreversible cytopathic effects in primary cardiomyocytes. J Med Virol. 2005;75:290-294.
18. Pallansch MA, Roos RP. Enteroviruses: poliovirus, coxsackievi-ruses, exhoviruses, and newer enteroviruses. In: Knipe DM, How-ley PM, eds. Field Virology. Philadelphia: Lippincott Williams & Wilkins; 2007:839-894.
19. Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol. 2003;4:457-467.
20. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-498.
21. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006;13:541-552.
22. Schubert S, Grunert HP, Zeichhardt H, Werk D, Erdmann VA, Kurreck J. Maintaining inhibition: siRNA double expression vectors against coxsackieviral RNAs. J Mol Biol. 2005;346:457-465.
23. Ahn J, Jun ES, Lee HS, et al. A small interfering RNA targeting coxsackievirus B3 protects permissive HeLa cells from viral challenge. J Virol. 2005;79:8620-8624.
24. Merl S, Michaelis C, Jaschke B, Vorpahl M, Seidl S, Wessely R. Targeting 2A protease by RNA interference attenuates coxsackieviral cytopathogenicity and promotes survival in highly susceptible mice. Circulation. 2005;111:1583-1592.
25. Kim YJ, Ahn J, Jeung SY, et al. Recombinant lentivirus-delivered short hairpin RNAs targeted to conserved coxsackievirus sequences protect against viral myocarditis and improve survival rate in an animal model. Virus Genes. 2008;36:141-146.
26. Jun EJ, Nam YR, Ahn J, et al. Antiviral potency of a siRNA targeting a conserved region of coxsackievirus A24. Biochem Biophys Res Commun. 2008;376:389-394.
27. Chen D, Texada DE, Duggan C, Deng Y, Redens TB, Langford MP. Caspase-3 and -7 mediate apoptosis of human Chang's conjunctival cells induced by enterovirus 70. Virology. 2006;347:307-322.
28. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003;31:3406-3415
29. Lee HS, Ahn J, Jun EJ, et al. A novel program to design siRNAs simultaneously effective to highly variable virus genomes. Biochem Biophys Res Commun. 2009;384:431-435
30. Brown KM, Chu CY, Rana TM. Target accessibility dictates the potency of human RISC. Nat Struct Mol Biol. 2005;12:469-470.
31. Schubert S, Grunweller A, Erdmann VA, Kurreck J. Local RNA target structure influences siRNA efficacy systematic analysis of intentionally designed binding regions. J Mol Biol. 2005;348:883-893
32. Martinez J, Tuschl T. RISC is a 5' phosphomonoester-producing RNA endonuclease. Genes Dev. 2004;18:975-980.
33. Jinek M, Doudna JA. A three-dimensional view of the molecular machinery of RNA interference. Nature. 2009;457:405-412.
34. Song JJ, Smith SK, Hannon GJ, Joshua-Tor L. Crystal structure of Argonaute and its implications for RISC slicer activity. Science. 2004;305:1434-1437.
35. Ameres SL, Martinez J, Schroeder R. Molecular basis for target RNA recognition and cleavage by human RISC. Cell. 2007;130:101-112.
36. Morishima C, Polyak SJ, Ray R, et al. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C J Infect Dis. 2006;193:931-940.
37. Gmyl AP, Pilipenko EV, Maslova SV, Belov GA, Agol VI. Functional and genetic plasticities of the poliovirus genome: quasi-infectious RNAs modified in the 5'-untranslated region yield a variety of pseudorevertants.J Virol. 1993;67:6309-6316.
38. Lee HS, Ahn J, Jee Y, et al. Universal and mutation-resistant anti-enteroviral activity: potency of small interfering RNA complementary to the conserved cis-acting replication element within the enterovirus coding region. J Gen Virol. 2007;88:2003-2012.
39. van Ooij MJ, Vogt DA, Paul A, et al. Structural and functional characterization of the coxsackievirus B3 CRE(2C): role of CRE(2C) in negative- and positive-strand RNA synthesis. J Gen Virol. 2006;87:103-113
40. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8:129 -138.
41. Shen JR,Samul RL, Silva H, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 2006;13:225-234.
42. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8:173-184.
43. Zhang W, Yang H, Kong X, et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med. 2005;11:56-62.